Affordable Access

deepdyve-link
Publisher Website

Update on omicron variant: What we know so far

Authors
  • Choudhary, Gajendra
  • Prajapat, Manisha
  • Kumaravel, J
  • Prabha, Praisy K
  • Sarma, Phulen
  • Handa, Vrishbhanu
  • Kaur, Harminder
  • Patel, Ajay Prakash
  • Medhi, Bikash
Type
Published Article
Journal
Indian Journal of Pharmacology
Publisher
Wolters Kluwer - Medknow
Publication Date
Mar 18, 2022
Volume
54
Issue
1
Pages
41–45
Identifiers
DOI: 10.4103/ijp.ijp_955_21
PMID: 35343206
PMCID: PMC9012418
Source
PubMed Central
Keywords
Disciplines
  • Short Communication
License
Unknown

Abstract

The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in any of the variants detected so far. The majority of these mutations are present in spike protein, contributing to its ability to escape the currently available neutralizing antibodies and vaccines, as well as increasing the chances of reinfection. This brief communication provides an insight into mutations detected in the omicron variant and their impact on currently available interventions against SARS-CoV-2 and the need for a booster dose. We also discuss the severity status of infection due to this variant. Additionally, we highlight the hypothesis supporting the association of high HIV prevalence and the appearance of the omicron variant of SARS-CoV-2 in immune-compromised individuals.

Report this publication

Statistics

Seen <100 times